Information about Imetelstat: the first clinical stage telomerase inhibitor



JnJ to present pre-clinical results on imetelstat-venetoclax combination therapy for AML at AACR 2017


Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosis in vitro and increases survival in vivo in acute myeloid leukemia

Date/time: April 3, 2017, 8:00 - 12:00 PM

Location: Walter E. Washington Convention Center
Washington, D.C.

Presenters/Authors: Joshua J. Rusbuldt, Leopoldo Luistro, Diana Chin, Melissa Smith, Amy Wong, Margarita Romero, Aleksandra Rizo, Jacqueline Bussolari, Fei Huang, Amy (Kate) Sasser (all from Janssen Research & Development, LLC, Spring House, PA)


Geron announces 2016 Annual Meeting of Stockholders

Tuesday, May 17, 2016 7:00 p.m. ET

Location Westin San Francisco Airport
One Old Bayshore Highway
Millbrae, CA, 94030

Conference Call: 877-303-9139 (U.S.); 760-536-5195 (international); conference ID 72479234
Webcast (audio-only):

Geron stockholders accessing the annual meeting by telephone will be invited to ask a question during the question and answer session. Geron stockholders may also submit a question in advance of the meeting by emailing

Ayalew Tefferi to present at ASCO2016, 6 June 8:00 AM - 11:30 AM

Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Abstract TPS7079, Poster Session, Poster Board #67a

The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study.

To be found through the iPlanner of the ASCO2016 website.

Abstracts will be available at, on May 18th, at 5:00pm EDT.

Geron to Present at the the Needham Healthcare Conference on 12 April 2016

MENLO PARK, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the 15th Annual Needham Healthcare Conference in New York at 8:40 a.m. Eastern Time on Tuesday, April 12, 2016.

Geron to present at the RBC Captial Markets 2016 Global Healthcare Conference on 23 February 2016

Slides available through Geron Homepage:

AACR 2016: 2 presentations on imetelstat and 3 about telomerase.

All 5 presentations are in the session 'Molecular and Cellular Biology / Genetics' on April 19, 08.00 - 12.00 AM.

Abstract Number: 2731
Presentation Title: Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat , a telomerase inhibitor, in AML cell lines

Abstract Number: 2732
Presentation Title: Myelosuppression in patients treated with the telomerase inhibitor imetelstat is not mediated through activation of toll-like receptors

For a program overview click here .


ASH 2015 (5-8 December 2015): abstracts of the 57th Annual Meeting Program and Exhibition are available

You may search for particular presentations by typing key words, an author's name, or the title in the box below. You may specify the type of search, i.e. whether you want to see pages that contain any or all of the words you specify. You will find 5 matches on 'imetelstat'.

ASH 2015: Scientific Meeting on Telomeres and Bone Marrow Failure

The relevance of telomeres to the pathogenesis and outcomes of bone marrow failure and other diseases is becoming increasingly apparent, extending beyond the rare telomere biology disorder, dyskeratosis congenita. Speakers are:

Steven Artandi, MD, PhD
Stanford University School of Medicine
Stanford, CA
Mechanisms Governing Disruption of Telomere Maintenance in Dyskeratosis Congenita

Maria A. Blasco, PhD
Spanish National Cancer Research Center - CNIO, Madrid, Spain
Therapeutic Strategies for the Treatment of Telomere-Associated Diseases

Mary Armanios, MD
Johns Hopkins University School of Medicine, Baltimore, MD
Extrahematopoietic Manifestations of Telomere Defects

May 13, 2015: Geron to Present at the Bank of America Merrill Lynch Healthcare Conference

MENLO PARK, Calif., April 27, 2015

Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2015 Healthcare Conference in Las Vegas at 3:40 p.m. Pacific Time on Wednesday, May 13. The presentation will include a review of the study design of the planned Phase 2 clinical trial of imetelstat in myelofibrosis patients. Janssen Biotech, Inc. ("Janssen") will be conducting the study.

May 21, 2015: Ayalew Tefferi presents at 5th International Congress on Leukemia, Lymphoma and Myeloma

Cutting Edge Advances in Myeloproliferative Neioplasms (16.00 - 17.30)

  • Clonal Origination and Evolution in MPN
  • - Radek Skoda (University Hospital Basel, CH)
  • Prognostication and Treatment of ET, PV and PMF
  • - Ayalew Tefferi (Mayo Clinic, Minnesota, USA)
  • Contemporary Science and Practice in Mast Cell and Eosinophilic Disorders
  • - Animesh Pardanani (Mayo Clinic Rochester, Minnesota, USA)

Sept. 17-19: 2015 ASH Meeting on Hematologic Malignancies

ASH, the leading authority on malignant hematology, presents its newest clinical meeting. Hear the top experts in hematologic malignancies discuss the latest developments in clinical care and find answers to your most challenging patient care questions. Each presentation will showcase the speaker's evidence-based treatment approaches, ranging from standard of care, specialized disease complications, and novel agent discussions.